Ainnova Tech, Inc.
Category: AI in Healthcare
An AI-powered preventative health platform that uses retinal imaging and other biomarkers for early disease detection. Ainnova Tech, Inc. was founded in 2020. The company is led by Vinicio Vargas. Based in Nevada-based with headquarters in San Jose, Costa Rica, and Houston, Texas.. Team size: 10-50. Total funding raised: $520K in funding over 3 rounds. Latest round: Total funding $4.92M (Asiarath, Fuel Accelerator, PioneerCrest Ventures) - AI retinal imaging for diabetic retinopathy detection. Key investors include Fuel (Funding partner).
- Founded
- 2020
- Headquarters
- Nevada-based with headquarters in San Jose, Costa Rica, and Houston, Texas.
- Team size
- 10-50
- Total funding
- $520K in funding over 3 rounds
Value proposition
To provide accessible, low-cost, and non-invasive preventive health check-ups for early disease detection, such as diabetic retinopathy and dementia.
Products and solutions
Vision AI Platform, Automated Retinal Camera
Unique value
Leverages the retina as a 'new vital sign', combining AI-driven retinal analysis with other patient data to create a comprehensive, preventive health report.
Target customer
Healthcare providers, pharmacies, clinics, and public health organizations.
Industries served
Healthcare, HealthTech, Pharmaceuticals
Technology advantage
Proprietary AI algorithms (exclusive license for four), development of a low-cost automated retinal imaging device for accessible screening, and a focus on integrating multiple data sources for broader disease detection.
How they differentiate
Ainnova differentiates by creating an accessible, low-cost screening platform intended for use in non-traditional settings like pharmacies, and by aiming to expand its detection capabilities beyond diabetic retinopathy to other conditions like dementia.
Main competitors
AEYE Health, Eyenuk Inc., Health Catalyst Inc.
Key partnerships
Avant Technologies, Inc. (Joint Venture and potential acquirer), Grupo Dökka (including Fischel Pharmacies and La Bomba Pharmacies)
Notable customers
Grupo Dökka, Fischel Pharmacies, La Bomba Pharmacies
Major milestones
Formed a joint venture with Avant Technologies. Entered into a non-binding Letter of Intent for a business combination with Avant Technologies. Finalizing the prototype of its automated retinal camera. Launched first diabetic retinopathy screenings in collaboration with leading pharmacy chains in Central America.
Growth metrics
Not publicly disclosed. Growth is demonstrated by the finalization of its device prototype and the initiation of commercial screening programs.
Market positioning
Positioned as an innovator in accessible, preventative diagnostics, aiming to democratize early health screening through a combination of AI software and low-cost hardware.
Geographic focus
Initial rollout and screenings are focused on Central America (Costa Rica, Nicaragua, Panama), with corporate presence in the USA (Nevada, Texas), indicating a focus on the Americas.
Patents and IP
In talks to license or acquire patented early disease detection technology; currently holds an exclusive license for four algorithms integrated into its Vision AI platform.
About Vinicio Vargas
Vinicio Vargas is the Founder and CEO of Ainnova Tech, Inc. He is a visionary entrepreneur with a passion for using technology to solve real-world problems. He has a background in technology and has been instrumental in the development of Ainnova Tech's AI-powered preventative health platform.
Official website: https://www.ainnovatech.com